Case File
efta-efta01135796DOJ Data Set 9OtherFrom: Eileen Alexanderson
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01135796
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Eileen Alexanderson
To: 'Jeffrey Epstein' [email protected]>
Subject: FW: Section 734
Date: Mon, 13 May 2013 19:01:53 +0000
Attachments:
From: Fenn, Patrick [mallto:
Sent: Saturday, April 06, 2013 1:03 PM
To: Eileen Alexanderson; 'Clapp, Ada'; 'Thomas Turrin'
Subject: FW: Section 734
Hi All.
Recall that the prior summaries of outcomes was based on the fact that the section TRA
benefit attributable to the Tufts gain in the deferral scenarios would be zero under the
current TRA. The attached deck has been modified to reflect the payment of 55% of the TRA
benefits on the Tufts gain in each relevant scenario (as well as changing the assumption on
page 4) as though Josh (or Marc) were the first partner out, based on a new assumption that
the TRA can be amended to include the section 734(b) basis step up. As we expected, this
had the greatest effect on the 5-year deferral scenarios (it's still not a good trade at 5 years,
but not as bad as it was) with a bit of a pick up at 20 years (NPV of $9M for Leon and $6M
for Marc and Josh using a 7.5% discount rate). The break even discount rate for the 20 year
scenario is now 5%. Of course, the TRA benefit for the Tufts gain step up will be
progressively larger for the later exchanging partners as a result of the transfers
progressively increasing APO Corp's interest in AMH. That would increase the NPV of the
TRA benefit attributable to the section 734(b) step up, but the later in time that step up
occurs (beyond the 20th year assumed in the model) the smaller the NPV of the additional
TRA benefit relative to the base case.
We are running one more scenario: one that assumes an amendment to the TRA to cover
basis step up in the deferral scenario, a 20-year guarantee by each partner (more likely an
SPV that owns an interest in BRH) and retention by each partner of at least a 1 percent
interest for the 20 years, with all the guarantees expiring in the 20th year. The idea is to see
if in that situation the full Tufts gain benefit can be delivered to each partner for its pro rata
share of the full Tufts gain (albeit beginning in the 20th year). Hope to have that sometime
this afternoon.
One additional issue that impacts the TRA benefit in the deferral scenario - the so-called
anti-churning rules, which we are still analyzing. These rules prevent refreshing
depreciable basis in property that the transferor owned or had a prior interest in, if that
interest falls within the description of various hyper-technical rules. We do not believe that
those rules would prevent a basis step up on an exchange of the units, but the manner in
which they apply to the step up at the end of the deferral scenario is different than in the
exchange context.
EFTA01135796
Regards
IRS Circular 230 Notice Requirement: This communication is not given in the form of a covered
opinion, within the meaning of Circular 230 issued by the United States Secretary of the Treasury.
Thus, we are required to inform you that you cannot rely upon any tax advice contained in this
communication for the purpose of avoiding United States federal tax penalties. In addition, any tax
advice contained in this communication may not be used to promote, market or recommend a transaction
to another party.
The information contained in this e-mail message is intended only for the personal and confidential
use of the recipient(s) named above. If you have received this communication in error, please notify
us immediately by e-mail, and delete the original message.
This email and any files transmitted with it are confidential
and intended solely for the person or entity to whom they are
addressed and may contain confidential and/or privileged
material. Any review, retransmission, dissemination or
other use of, or taking of any action in reliance upon this
information by persons or entities other than the intended
recipient is prohibited. If you have received this email in
error please contact the sender and delete the material from
any computer.
Apollo Global Management, LLC
EFTA01135797
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Wire Ref
refreshingRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
OtherUnknown
FEDWIRE PAYMENT DEBIT ADVICE
DOJ EFTA Data Set 10 document EFTA01273102
16p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.